Cephalon adds to clinical disappointment in 1997.
Glaser
V
V
D000690:Amyotrophic Lateral Sclerosis / Q000628:therapy; D001709:Biotechnology; D002986:Clinical Trials as Topic; D004345:Drug Industry; D006133:Growth Substances / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D036341:Intercellular Signaling Peptides and Proteins; D011994:Recombinant Proteins / Q000627:therapeutic use; D017211:Treatment Failure; D014481:United States; D014486:United States Food and Drug Administration
D006133:Growth Substances; D036341:Intercellular Signaling Peptides and Proteins; D011994:Recombinant Proteins; C065700:myotrophin; D007334:Insulin-Like Growth Factor I